Building a strong team of industry experts as clinical programmes progress
- Dr Austin Smith, Deputy Chief Medical Officer
1st August 2023 – VasoDynamics Ltd, the pharmaceutical company developing therapies for common complexities in cancer treatment, today announces key appointment to support the management team.
Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:
“With our platform products and clinical programmes progressing rapidly, supported by our successful seed funding investment from LongevityTech Fund and Open Philanthropy (Good Ventures Foundation), it is vitally important that we have the industry expertise to strengthen the clinical management team and lift the company’s profile into the next strategic stage. We are delighted to announce the appointments of Dr Austin Smith as Deputy Medical Officer, who brings invaluable experience to the management team as we enter our next phase of clinical and commercial development.”
Dr Austin Smith, Deputy Chief Medical Officer
Austin is a qualified GMC registered Medical Oncologist with various escalating positions across all oncology functional disciplines in both adult and paediatric units. He has more than 15 years industry experience as a Medical Director or Chief Medical Officer leading clinical development and contributing expertise in drug development covering multiple fields such as radiopharmaceuticals, reformulated/repurposed drugs, viral products, vaccines, immunomodulator agents, antibodies, and medical devices.
Austin said “I am delighted to have joined VasoDynamics at such an exciting time of the company’s development, with several programmes entering late-stage and clinical development phase. I am looking forward to working with the executive team and clinical team as we accelerate the NG11-2 clinical trial progress to enable potential commercial opportunities.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO +44 7969132263
Gary Bower, COO +44 7960388412
Notes to Editors:
VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating, and often dose-limitin,g complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve selective protection of normal tissue during cancer treatment whilst facilitating anti-cancer therapy efficacy.